DM
VRTX icon

Deerfield Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Deerfield Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,276
Closed -$598K – 658
2024
Q2 		$598K Buy
+1,276
New +$554K 0.01% 226
2015
Q4 		– Sell
-18,500
Closed -$1.93M – 125
2015
Q3 		$1.93M Buy
+18,500
New +$2.38M 0.07% 114
2014
Q3 		– Sell
-92,500
Closed -$8.76M – 144
2014
Q2 		$8.76M Buy
92,500
+14,000
+18% +$982K 0.35% 69
2014
Q1 		$5.55M Buy
+78,500
New +$6.22M 0.23% 89

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Deerfield Management's VRTX Position: Q3 2024 in Review

Deerfield Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 1,276 shares — an estimated $598K sold.

Deerfield Management first reported a position in VRTX in Q1 2014 and held it in 4 quarters. The position peaked at $8.76M in Q2 2014. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Deerfield Management reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Deerfield Management sold 1,276 Vertex Pharmaceuticals shares in Q3 2024, an estimated $598K.
  • Deerfield Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 4 quarters.
  • Deerfield Management's Vertex Pharmaceuticals position peaked at $8.76M in Q2 2014.
  • 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.